Role of Melatonin in Schizophrenia

Schizophrenia is a chronic mental disease that disturbs several cognitive functions, such as memory, thought, perception and volition. Schizophrenia’s biological etiology is multifactorial and is still under investigation. Melatonin has been involved in schizophrenia since the first decades of the twentieth century. Research into melatonin regarding schizophrenia has followed two different approaches. The first approach is related to the use of melatonin as a biological marker. The second approach deals with the clinical applications of melatonin as a drug treatment. In this paper, both aspects of melatonin application are reviewed. Its clinical use in schizophrenia is emphasized.

• Publication year

  2013

• Venue

  International Journal of Molecular Sciences

• Publication date

  2013-04-25

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3390/ijms14059037PMID 23698762PMCID 3676771
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen Rapidly Enhances Incisional Pain of Ovariectomized Rats Primarily through the G Protein-Coupled Estrogen Receptor

  2014cited by this paper
• Interventions to reduce antipsychotic polypharmacy: a systematic review.

  2013cited by this paper
• Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation

  2012cited by this paper
• Sleep and circadian rhythm disruption in schizophrenia†

  2012cited by this paper
• Benzodiazepines for schizophrenia.

  2012cited by this paper
• Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction

  2012cited by this paper
• Effectiveness of melatonin in tardive dyskinesia.

  2011cited by this paper
• Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year longitudinal study of schizophrenia and bipolar disorder.

  2011cited by this paper
• Melatonin as a natural ally against oxidative stress: a physicochemical examination

  2011cited by this paper
• Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol

  2011cited by this paper
• Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls

  2011cited by this paper
• Study of OH• Radicals in Human Serum Blood of Healthy Individuals and Those with Pathological Schizophrenia

  2011cited by this paper
• P.3.b.001 Seasonality of serum melatonin concentrations in paranoid schizophrenic inpatients

  2010cited by this paper
• Melatonin: a pleiotropic molecule regulating inflammation.

  2010cited by this paper
• Melatonin and Structurally-Related Compounds Protect Synaptosomal Membranes from Free Radical Damage

  2010cited by this paper
• Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep.

  2010cited by this paper
• P03-317 - Agomelatine Facilitates Benzodiazepine Discontinuation in Schizophrenia with Severe Insomnia

  2010cited by this paper
• Melatonin induces pro‐apoptotic signaling pathway in human pancreatic carcinoma cells (PANC‐1)

  2010cited by this paper
• Clinical uses of melatonin: evaluation of human trials.

  2010cited by this paper
• International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors

  2010cited by this paper
• Melatonin Metabolism in the Central Nervous System

  2010cited by this paper
• Melatonin and circadian biology in human cardiovascular disease

  2010cited by this paper
• Melatonin as a potential therapeutic agent in psychiatric illness

  2009cited by this paper
• Benzodiazepines for schizophrenia.

  2007cited by this paper
• Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study.

  2007cited by this paper
• Role of melatonin in upper gastrointestinal tract.

  2007cited by this paper
• One molecule, many derivatives: A never‐ending interaction of melatonin with reactive oxygen and nitrogen species?

  2007cited by this paper
• The circadian visual system, 2005.

  2006cited by this paper
• Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine.

  2006influential reference
• [Melatonin therapeutic use in psychiatry: a 39 year bibliographic study].

  2006cited by this paper
• Altered Glutathione Redox State in Schizophrenia

  2005cited by this paper
• Oxidative stress in blood platelets from schizophrenic patients

  2005cited by this paper
• Regulation of antioxidant enzymes: a significant role for melatonin

  2004cited by this paper
• Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects

  2004cited by this paper
• Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin

  2003cited by this paper
• Biorhythms and pineal gland.

  2003cited by this paper
• Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia.

  2003cited by this paper
• Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia.

  2003cited by this paper
• Effects of exogenous melatonin on pituitary hormones in humans.

  2001cited by this paper
• Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.

  2001cited by this paper
• Seguridad en el uso de la melatonina

  2001cited by this paper
• A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia.

  2001cited by this paper
• Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry.

  2001cited by this paper
• Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study.

  2001cited by this paper
• [Safety in melatonin use].

  2001cited by this paper
• Randomized, double‐blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment

  2000cited by this paper
• Is melatonin treatment effective for tardive dyskinesia?

  2000cited by this paper
• First-night effect of melatonin treatment in patients with chronic schizophrenia.

  2000cited by this paper
• Melatonin improves sleep quality of patients with chronic schizophrenia.

  2000cited by this paper
• Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach.

  1999cited by this paper
• Cyclic 3-Hydroxymelatonin: A Melatonin Metabolite Generated as a Result of Hydroxyl Radical Scavenging

  1999cited by this paper
• Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients.

  1998influential reference
• Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report.

  1997cited by this paper
• Daytime melatonin administration in elderly good and poor sleepers: effects on core body temperature and sleep latency.

  1997cited by this paper
• A schizophrenic patient with an arrhythmic circadian rest-activity cycle.

  1997cited by this paper
• Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.

  1997influential reference
• The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland.

  1997cited by this paper
• Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes

  1996cited by this paper
• Melatonin in relation to physiology in adult humans

  1996cited by this paper
• Neural control of the pineal gland.

  1995influential reference
• Free radical mechanisms in schizophrenia and tardive dyskinesia.

  1994cited by this paper
• The circadian visual system.

  1994cited by this paper
• Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia.

  1994cited by this paper
• Distribution of melatonin in mammalian tissues: The relative importance of nuclear versus cytosolic localization

  1993cited by this paper
• Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics.

  1992cited by this paper
• The Ciliary Body - The Third Organ Found to Synthesize Indoleamines in Humans

  1992cited by this paper
• Regulation of pineal serotonin N-acetyltransferase activity.

  1992cited by this paper
• Melatonin: The chemical expression of darkness

  1991cited by this paper
• Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients

  1991cited by this paper
• Acute Cerebral Hemorrhage Changes the Nocturnal Surge of Plasma Melatonin in Humans

  1990cited by this paper
• Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects.

  1990cited by this paper
• Nocturnal plasma melatonin levels in schizophrenic patients.

  1989cited by this paper
• Melatonin and psychiatry.

  1988cited by this paper
• Synchronisation of a disturbed sleep-wake cycle in a blind man by melatonin treatment.

  1988cited by this paper
• Benzodiazepines in schizophrenia.

  1986cited by this paper
• Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial.

  1986cited by this paper
• Tardive dyskinesia: prevalence, incidence, and risk factors.

  1985cited by this paper
• Melatonin immunoreactivity in cerebrospinal fluid of schizophrenic patients and healthy controls.

  1984influential reference
• Effect of psychotropic drugs on [14c]tryptophan metabolism in cultured rat pineal gland

  1983cited by this paper
• Effect of psychotrophic drugs on [14C]tryptophan metabolism in cultured rat pineal gland.

  1983cited by this paper
• MELATONIN/CORTISOL RATIO IN PSYCHIATRIC ILLNESS

  1982cited by this paper
• HUMAN POST‐MORTEM PINEAL ENZYME ACTIVITY

  1981cited by this paper
• Withdrawal from long-term benzodiazepine treatment.

  1981cited by this paper
• The Schizophrenia Syndrome: Examples of Biological Tools for Subclassification

  1981cited by this paper
• The effect of neuroleptic drugs on serum and cerebrospinal fluid melatonin concentrations in psychiatric subjects

  1979cited by this paper
• Radioimmmunoassay for melatonin in human serum.

  1978cited by this paper
• Analysis of melatonin in human plasma by gas chromatography negative chemical ionization mass spectrometry.

  1978cited by this paper
• The measurement of melatonin in mammalian tissues and body fluids.

  1978cited by this paper
• ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC PATIENTS TREATED WITH CHLORPROMAZINE

  1977cited by this paper
• The pineal and psychiatry: a review

  1977cited by this paper
• The effects of oral melatonin on skin color and on the release of pituitary hormones.

  1977cited by this paper
• Suppression of human growth hormone secretion by melatonin and cyproheptadine.

  1974cited by this paper
• Effects of aqueous pineal extract in chronic schizophrenia.

  1974cited by this paper
• Effects of aqueous pineal extract in chronic schizophrenia.

  1974cited by this paper
• Inhibition of catecholamine oxidation by indoles.

  1972cited by this paper
• Melatonin metabolism: neural regulation of pineal serotonin: acetyl coenzyme A N-acetyltransferase activity.

  1971cited by this paper
• Effect of 5-methoxytryptophol and melatonin on uterine weight responses to human chorionic gonadotrophin.

  1970cited by this paper
• Studies on the relation of melatonin to sleep.

  1968cited by this paper
• A biochemical concept of mental disease.

  1961cited by this paper
• A pilot study comparing the effects of pineal extract and a placebo in patients with chronic schizophrenia.

  1960cited by this paper

• Efficacy and safety of anti-inflammatory drug-assisted treatment of symptoms in patients with schizophrenia: a meta-analysis

  2026cites this paper
• Salience and executive network connectivity analyses in schizophrenia during emotional memory tasks

  2025cites this paper
• A novel insight into the femtosecond induced nonlinear response of monoamine neurotransmitters through experimental and in silico approaches

  2025cites this paper
• A Meta-Analysis of Melatonin Effects on Behavior of Rats Kept in Standard Conditions

  2025cites this paper
• Comprehensive bioinformatics analysis identifies hub genes associated with immune cell infiltration in early-onset schizophrenia

  2025cites this paper
• The dissemination, health risks, and mitigation approaches of antibiotic resistance genes in the gut microbiome

  2025cites this paper
• Melatonin–Dopamine Crosstalk: A Central Axis in Circadian Regulation and Clinical Chronopharmacology

  2025cites this paper
• ROLE OF MELATONIN IN THE MANAGEMENT OF SLEEP DISORDERS IN SCHIZOPHRENIA: A LITERATURE REVIEW

  2025cites this paper
• Relevance of diet in schizophrenia: a review focusing on prenatal nutritional deficiency, obesity, oxidative stress and inflammation

  2024cites this paper
• Enhancing Transcriptomic Insights into Neurological Disorders Through the Comparative Analysis of Shapley Values

  2024cites this paper
• Exploring melatonin’s therapeutic potential in neurological disorders: a review of current evidence

  2024cites this paper
• TREATMENT OF SCHIZOPHRENIA IN ELDERLY PATIENTS

  2024cites this paper
• Analysis of single-cell transcriptome data from a mouse model implicates protein synthesis dysfunction in schizophrenia

  2024cites this paper
• Causal link between gut microbiome and schizophrenia: a Mendelian randomization study

  2024cites this paper
• Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders

  2024cites this paper
• Melatonin as mitochondria-targeted drug.

  2023cites this paper
• Does melatonin administration reduce the incidence of postoperative delirium in adults? Systematic review and meta-analysis

  2023cites this paper
• Melatonin in Neurodevelopmental Disorders: A Critical Literature Review

  2023cites this paper
• Metabolome subtyping reveals multi-omics characteristics and biological heterogeneity in major psychiatric disorders.

  2023cites this paper
• Sulfur-containing amino acids and risk of schizophrenia.

  2023cites this paper
• Factors and Mechanisms Influencing Conjugation In Vivo in the Gastrointestinal Tract Environment: A Review

  2023cites this paper
• Evaluating the Effect of Melatonin on Positive and Negative Symptoms of Schizophrenic Patients: A Randomized Placebo-Controlled Study

  2023cites this paper
• Mechanisms of Ferritinophagy and Ferroptosis in Diseases

  2023cites this paper
• Biological Rhythm and Neuropsychiatric Disorders

  2022cites this paper
• Pineal morphology of the clinical high-risk state for psychosis and different psychotic disorders.

  2022cites this paper
• Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis.

  2022cites this paper
• Is there a role for melatonin in the treatment of schizophrenia?

  2022cites this paper
• Pengembangan Instrumen Perilaku Mencari Bantuan pada Generasi Z di Suku Madura

  2022cites this paper
• Melatonin for the prevention of postoperative delirium in older adults: a protocol for a systematic review and meta-analysis

  2022cites this paper
• Impact of circadian clock dysfunction on human health

  2022cites this paper
• A revision of polymeric nanoparticles as a strategy to improve the biological activity of melatonin.

  2022cites this paper
• Pyroptosis and Intervertebral Disc Degeneration: Mechanistic Insights and Therapeutic Implications

  2022cites this paper
• COGNITIVE IMPAIRMENT IN PSYCHOSIS LANDSCAPE REPORT

  2022cites this paper
• Discuss the Method of Channeling Fu and Removing Evil in Spirit Application in Schizophrenia Based on Brain-Gut Correlation Theory

  2022cites this paper
• The knowledge of Schizophrenia among health- related students in Umm Al-Qura University: A cross sectional survey

  2022cites this paper
• Systematic Review of the Therapeutic Role of Apoptotic Inhibitors in Neurodegeneration and Their Potential Use in Schizophrenia

  2022cites this paper
• Self-care e schizofrenia: risultati di una revisione narrativa della letteratura

  2022cites this paper
• Mendelian randomization study on the effect of tumor necrosis factor on schizophrenia

  2022cites this paper
• Candidates for Drug Repurposing to Address the Cognitive Symptoms in Schizophrenia

  2022cites this paper
• Neuroprotective effect of agomelatine in rat model of psychosis: Behavioural and histological evidence

  2021cites this paper
• Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.

  2021cites this paper
• Post-schizophrenia comorbid depressive disorder and insomnia treated by acupuncture combined with Chinese medicine: A retrospective case series based on JBI reporting checklist

  2021cites this paper
• Therapeutic use of melatonin in schizophrenia: A systematic review

  2021cites this paper
• Treatment of antipsychotic-induced parkinsonism in schizophrenic patients

  2021cites this paper
• Hyperphosphorylation of Tau Due to the Interference of Protein Phosphatase Methylesterase-1 Overexpression by MiR-125b-5p in Melatonin Receptor Knockout Mice

  2021cites this paper
• Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry

  2021cites this paper
• Effect of Haloperidol and Risperidone on Serum Melatonin and GAP-43 in Patients with Schizophrenia: A Prospective Cohort Study

  2021cites this paper
• Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder

  2021cites this paper
• Multi-Omics Approaches to Study Signaling Pathways

  2020cites this paper
• Melatonin Use in Psychiatry-Quo Vadis?

  2020cites this paper
• An Ensemble Approach to Predict Schizophrenia Using Protein Data in the N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways

  2020cites this paper
• Physiological and pharmacological perspectives of melatonin

  2020cites this paper
• Melatonin recovers sleep phase delayed by MK‐801 through the melatonin MT2 receptor‐ Ca2+‐CaMKII‐CREB pathway in the ventrolateral preoptic nucleus

  2020cites this paper
• Remodeling agro-industrial and food wastes into value-added bioactives and biopolymers

  2020cites this paper
• The preclinical discovery and development of agomelatine for the treatment of depression

  2020cites this paper
• Schizophrenia-like behavior is not altered by melatonin supplementation in rodents.

  2020cites this paper
• Novel Melatonin Derivatives: Synthesis, Anticancer Evaluations and Molecular-Docking Study

  2020cites this paper
• Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia

  2019cites this paper
• Oxidative stress and related gene expression effects of cyfluthrin in human neuroblastoma SH-SY5Y cells: Protective effect of melatonin.

  2019cites this paper
• Melatonin modulates inflammatory mediators and improves olanzapine-induced hepatic steatosis in rat model of schizophrenia.

  2019cites this paper
• Rythmes circadiens et troubles psychiatriques

  2019cites this paper
• Melatonin MT1 receptor as a novel target in neuropsychopharmacology: MT1 ligands, pathophysiological and therapeutic implications, and perspectives.

  2019cites this paper
• Pineal gland and schizophrenia: A systematic review and meta-analysis.

  2019cites this paper
• Reduced pineal gland volume across the stages of schizophrenia.

  2019cites this paper
• Historeceptomics: Integrating a Drug’s Multiple Targets (Polypharmacology) with Their Expression Pattern in Human Tissues

  2018cites this paper
• Melatonin and sleep in schizophrenia: a commentary

  2018cites this paper
• Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study

  2018cites this paper
• Clinical Implications of the Timed Autonomic Nervous System

  2018cites this paper
• Reduced Efficacy of d-Amphetamine and 3,4-Methylenedioxymethamphetamine in Inducing Hyperactivity in Mice Lacking the Postsynaptic Scaffolding Protein SHANK1

  2018cites this paper
• Melatonin: Pharmacology, Functions and Therapeutic Benefits

  2017cites this paper
• A three-month longitudinal study of changes in day/night serum total antioxidant capacity in paranoid schizophrenia

  2017cites this paper
• Low levels of serum total antioxidant capacity and presence at admission and absence at discharge of a day/night change as a marker of acute paranoid schizophrenia relapse.

  2017cites this paper
• Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia

  2017influential citation
• Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms

  2016cites this paper
• Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study

  2016cites this paper
• The Potential Role of Melatonin on Mental Disorders: Insights from Physiology and Pharmacology

  2016cites this paper
• Melatonin “Pearls” in Psychiatry

  2016cites this paper
• The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment.

  2016cites this paper
• Melatonin treatment during the incubation of sensitization attenuates methamphetamine-induced locomotor sensitization and MeCP2 expression.

  2016cites this paper
• Advancing role of melatonin in the treatment of neuropsychiatric disorders

  2016cites this paper
• Sleep and Schizophrenia

  2016cites this paper
• A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain.

  2015cites this paper
• Descartes and His Peculiar Sleep Pattern

  2015cites this paper
• Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness.

  2015cites this paper
• Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression

  2015cites this paper
• Conception, synthèse et évaluation pharmacologique d’antidépresseurs potentiels : ligands mixtes des récepteurs mélatoninergiques MT1/MT2 et des récepteurs sérotoninergiques 5-HT2c

  2014cites this paper
• Women and schizophrenia: new findings

  2013cites this paper
• World Journal of Psychiatry

  year unknowncites this paper